



Manulife Dragon Growth Fund[†]

A flexible approach to capture opportunities in China and Hong Kong


- ✓ Potential growth opportunities from Hong Kong and China equities
- ✓ Leveraging consumption upgrade, innovations and policy tailwinds to spur growth
- ✓ Flexible allocation between China and Hong Kong equities

[†] The full name of the Fund is Manulife Global Fund — Dragon Growth Fund

The case for Hong Kong and China equities

China is leading the world's GDP growth

China's Two Sessions set out a modest growth target of "above 6%" for 2021 while IMF upgraded China's 2021 GDP growth forecast to 8.4%.




Source: IMF, World Economic Outlook, April 2021.

Consumption upgrade for value-added services

With consumers spending more on lifestyle-related services, property management companies providing these value-added services to the community are expected to do well with the increased demand in this space. The top-100 players of residential property management companies are expected to grow at 21% over 2020-25, doubling the market share to 48% in 2025 from 24% in 2020.

Revenue from basic services of property management companies in China* (USD mn)

2020-2025E(CAGR) for Top 100 players: **21%**




Source: Credit Suisse, 16 February 2021.

China policy tailwinds: Sustainability

Net carbon zero and self-sufficiency has been a top priority in China's policy agenda. Strengthening innovation to spur domestic growth are key for China's "dual circulation" strategy while a carbon neutrality pledge ensures renewable energy sources such as electric vehicles (EV) development remains a key sustainability initiative.

Market share of global EV battery manufacturers (2020)




Source: Citic Securities, Bloomberg, as of August 2020.

Leverage biotech innovation for quality healthcare

With an ageing population and the rapid emerging landscape for innovative drug discovery, notable potential upside is expected for the biologics market in China. In addition, industry consolidation and a more favourable regulatory environment should provide opportunities for pharmaceutical companies.

China biologics market sales* (USD bn)



Source: CICC Research, as of April 2020.

Why Manulife Dragon Growth Fund

Capturing growing trends: three key investment themes

Consumption upgrade



Property management services companies and electric vehicle brands should benefit from the trend in China's consumption upgrade.

R&D / innovation



China's government and corporations emphasise on R&D and innovation to improve competitiveness, especially in high technology, industrial applications, and healthcare sector.

Policy driven




The Chinese government may continue to support several key policy areas, such as import substitution tailwind for technology and healthcare.

Conviction is the key in stock selection

Our investment team holds a medium- to long-term view, but makes adjustments in the short-term according to market conditions. We aim to hold a concentrated portfolio with **40-55 stocks**¹.

Flexible allocation between China and Hong Kong equities

Our investment team makes flexible and dynamic allocations between China and Hong Kong equities, according to changes in market conditions, government policies and industry trends.



Award-winning team

Winning a wide range of awards for the **past 7 years**²

Morningstar Fund Awards Hong Kong 2021
Best Hong Kong Equity Fund



BENCHMARK Fund of the Year Awards 2020
Hong Kong Equity – Best-in-Class



About Manulife Investment Management

40+

Equity investment experts in the Greater China region

24+ years

of track record in managing the Fund

USD 789 bn

Assets under management and administration

Source: As of 31 March 2021. Note: Some professionals may support additional asset classes. Based in China, Manulife TEDA Fund Management Company Limited is a joint venture between Manulife (49%) and Northern International Trust (51%), part of the Tianjin TEDA Investment Holding Co. Ltd.

1. Manulife Investment Management, as of 30 June 2021. This is an illustrative guideline. Portfolio holdings and characteristics are subject to change at any time. Information about the asset allocation is historical and is not an indication of the future composition.

2. Manulife Investment Management (Asia), as of 28 February 2021. Awards issued by different sponsors are for reference only, and should not be construed as an endorsement of Manulife Investment Management, its affiliates or its products. Please refer to the respective websites of the sponsors of these awards for more information regarding the criteria and manner in which such awards are determined. Morningstar Awards Hong Kong 2021 are issued based on the best risk adjusted performance as of December 2020 within their Morningstar Categories or groupings of Morningstar Categories, subject to qualitative review. Morningstar Awards 2021 (c). Morningstar, Inc. All Rights Reserved. Awarded to Manulife Dragon Growth Fund AA HKD for the Best Hong Kong Equity Fund. Benchmark Fund of the Year Awards are issued based on the assessment criteria of the sponsor. Outstanding Achiever for 2014 and 2015, Retail Class – Best-in-class for 2016, House Award - Best-in-class for 2017, 2018 and 2020. This award reflects the performance of the Fund as of September of the year mentioned. Bloomberg BusinessWeek (Chinese Edition) Top Fund Awards 2015 are issued based on the assessment criteria of the sponsor and performance data of funds. This award reflects the performance of the Fund – Class A as of September of the year mentioned. Fund Selector Asia Awards 2017 are issued based on the assessment criteria of the sponsor and performance data of funds. This award reflects the performance of the Fund – Class A as of June 2016. Citywire Asia Awards are issued based on the assessment criteria of the sponsor and performance data of funds. Citywire Best Fund Manager Awards – Hong Kong Equity for 2016, 2018, 2020. reflecting the 3-year performance of the Fund as of December of the prior year (i.e. 2015, 2017, 2019). Citywire Best Fund Group Awards – Hong Kong Equity for 2017, 2018, 2019 and 2020, recognising the expertise of the group as a whole in managing money in specific investment sectors over seven years (i.e. Dec 2009 – Dec 2016, Dec 2010 – Dec 2017, Dec 2011 – Dec 2018 and Dec 2012 – Dec 2019).

Share class	AA(Accumulation)	AA (USD) MDIST (G)	AA (SGD Hedged) MDIST (G)
Investment objective	The Fund aims to achieve capital growth by investing at least 70% of its net assets in a diversified portfolio of equity and equity related securities of public companies which are listed in Hong Kong and/or, although not listed in Hong Kong, are listed on a stock exchange in any other jurisdiction and have substantial business interests in Hong Kong and/or China. Such equity and equity related securities include common stocks, preferred stocks and depositary receipts.		
Inception date	13 December 2016	14 December 2018	16 April 2020
ISIN code	LU1328277881	LU1813983027	LU2039709279
Bloomberg ticker	MADRGRA LX	MLHEAUM LX	MLHESHG LX
Base currency	USD		
Mode of subscription	Cash		
Minimum initial investment	USD 1,000 (or the equivalent in any other major currency)		
Distribution frequency	Annually	Monthly	Monthly
Management fee	1.50%		
Initial sales charge	Up to 5%		
Dealing frequency	Daily		
Investment manager	Manulife Investment Management (Hong Kong) Limited		
Fund Size	USD 609.74 million / SGD 819.73 million (as of 30 June 2021)		

*The above information may contain projections or other forward-looking statements regarding future events, targets, management discipline or other expectations. There is no assurance that such events will occur, and the future course may be significantly different from that shown here.

Important notes:

Manulife Global Fund (the "Company") is an open-ended investment company registered in the Grand Duchy of Luxembourg. The Manulife Global Fund — Dragon Growth Fund (the "Fund") is recognised under the Securities and Futures Act of Singapore for retail distribution. The Company has appointed Manulife Investment Management (Singapore) Pte. Ltd. as its Singapore Representative and agent for service of process in Singapore. The information provided herein does not constitute financial advice, an offer or recommendation with respect to the Fund.

Opinions, forecasts and estimates on the economy, financial markets or economic trends of the markets mentioned herein are not necessarily indicative of the future or likely performance of the Fund. **The Fund may use financial derivative instruments for efficient portfolio management and/or hedging.**

Investments in the Fund are not deposits in, guaranteed or insured by the manager and involve risks. Past performance of the manager or sub manager is not necessarily indicative of its future performance and any income accruing to them may fall or rise. Past performance of the Fund is not necessarily indicative of future performance. The value of units in the Fund and any income accruing to them may fall or rise. Past performance of the Fund is not necessarily indicative of future performance. Investors should read the prospectus, and seek advice from a financial adviser before deciding whether to purchase units in the Fund. A copy of the prospectus and the product highlights sheet can be obtained from Manulife or its distributors. In the event an investor chooses not to seek advice from a financial adviser, he should consider whether the Fund is suitable for him.

Distributions are not guaranteed. Investors should refer to the Singapore prospectus for the distribution policy of the Fund. The Directors of the Company shall have the absolute discretion to determine whether a distribution is to be made in respect of the Fund as well as the rate and frequency of distributions to be made. Distributions may be made out of (a) income, or (b) net capital gains, or (c) capital of the Fund, or (d) gross income while charging all or part of the fees and expenses to capital, or (e) any combination of (a), (b), (c) and/or (d). Past distribution yields and payments are not necessarily indicative of future distribution yields and payments. Any payment of distributions by the Fund is expected to result in an immediate decrease in the net asset value per share of the Fund.

This advertisement or publication has not been reviewed by the Monetary Authority of Singapore. Information is correct as of 30 June 2021.